Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels

Atherosclerosis

Volumn 133, Issue 1, 1997, Pages 123-133

  Alaupovic, Petar ^a   Heinonen, Therese ^b   Shurzinske, Linda ^b   Black, Donald M ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b PFIZER INC   (United States)

Author keywords

Atorvastatin; Cholesterol; Hydroxy methylglutaryl CoA reductase inhibitor; Lipoprotein particles; Triglycerides

Indexed keywords

APOLIPOPROTEIN; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030751279     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00119-6     Document Type: Article

References (37)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82.
2. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins H, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded clinical evaluation of lovastatin (EXCEL) study results. (1) Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
3. Tikkanen MJ, Bocanegra TS, Walker JF, Cook T. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol - a multicenter study. Am J Med 1989;87:S47-53.
4. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109(1):25-32.
5. Nawrocki JW, Weiss SR, Davidson MII, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
6. Black D. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In: Woodford FP, Davignon J, Sniderman A, editors. Atherosclerosis X. Amsterdam: Elsevier Science, 1995:307-310.
7. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Therapeut 1996;2:117-22.
8. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, Black DM. The lipid-lowering effect of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Therapeut 1996;18(5):853-63.
9. Bakker-Arkema RG, Davidson MH, Goldstein RI, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
11. Remmel PS, Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MR-FIT), I: use of a dietary monitoring tool. JAMA 1980;76:351-6.
12. Friedewald WT, Levy RI, Fredrickson DO. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Cole TG, Ferguson CA, Gibson DW. High-throughput B-quantification methods. Atherosclerosis 1994;108(Suppl):S191.
14. Lipid Research Clinics Program. Manual of laboratory operations, Vol. 1. Lipid and lipoprotein analysis. DHEW Publication No. (NIH) 75-628. Washington, DC: US Government Printing Office, 1974.
15. 2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. In: Cooper GR, editor. Selected methods of clinical chemistry, Vol. 10. Washington, DC: American Association of Clinical Chemistry, 1983:91-9.
16. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 1980;617:505-13.
17. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts-lipid and nonlipid factors. Circulation 1990;81:470-6.
18. Alaupovic P. David Rubenstein Memorial Lecture: the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem 1981;59:565-79.
19. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of apo A- and apo B-containing lipoprotein families. Prog Lipid Res 1991;30:105-38.
20. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH. Effects of lovastatin on apo A- and apo B-containing lipoprotein families in a subpopulation of patients participating in the monitored atherosclerosis regression study (MARS). Arterioscler Thromb 1994;14:1906-14.
21. Alaupovic P, Knight-Gibson C, Wang CS, Downs D, Koren E, Brewer HB Jr., Gregg RE. Isolation and characterization of an apoA-II-containing lipoprotein (LPA-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and Type V hyperlipoproteinemia. J Lipid Res 1991;32:9-19.
22. Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol 1997;in press.
23. Todd PA, Goa KL. Simvastatin - a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990;40:583-607.
24. Rubenfire M, Maciejko JJ, Blevins RD, Orringer C, Kobylak L, Rosman H. Southeastern Michigan Collaborative Group. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991;151:2234-40.
25. Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ, Wright JT. Efficacy and safety of once daily versus twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-55.
26. Alaupovic P. The significance of apolipoproteins for structure, function and classification of plasma lipoproteins. In: Bradley WA, Gianturco SH, Segrest JP, editors. Methods in enzymology. Plasma lipoproteins, Part C, Quantitation. San Diego: Academic Press, 1996;32-60.
27. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild to moderate/severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
28. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-22.
29. Agnani G, Bard JM, Candelier L, Lestavel-Delattre S, Fruchart JC, Clavey V. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arterioscler Thromb 1991;11:1021-9.
30. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.. Arterioscler Thromb Vasc Biol 1991;15:963-71.
31. Koren E, Košćec M, Corder C, Knight-Gibson C, Lee DM, Alaupovic P. Differential atherogenicity of complex apo B-containing lipoprotein particles. Atherosclerosis 1994;109:217-8.
32. Barbi G, Corder CN, Koren E, McConathy WJ, Ye SQ, Wilson P. Effect of pravastatin and cholestyramine on triglyceride-rich lipoprotein particles and Lp(a) in patients with type-Il hypercholesterolemia. Drug Develop Res 1991;27:297-306.
33. Bard JM, Parra HJ, Douste-Blazy P, Frachart JC. Effect of pravastatin, and HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1990;39:269-73.
34. Dallongeville J, Fruchart JC, Pfister P, Bard JM. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). J Intern Med 1991;236:95-101.
35. Bard JM, Parra HJ, Camare R, Luc G, Ziegler O, Dachet C, Bruckert E, Douste-Blazy P, Drouin P, Jacotot B, DeGennes JL, Keller U, Fruchart JC. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992;41:498-503.
36. Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein-B concentrations - comparison of gemfibrozil versus lovastatin therapy. JAMA 1990;264:2759-63.
37. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia-evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-93.